News

TAVT-135, an inhaled treatment candidate being developed for people with cystic fibrosis (CF) regardless of their underlying mutation type, was found to help normalize mucus production in a cell model of the disease. According to researchers from Tavanta Therapeutics, the treatment’s developer, the findings of their in vitro…

Scientists in New York are calling on the cystic fibrosis (CF) research community to take proactive steps to increase diversity in clinical trials — which now typically include a disproportionate number of non-Hispanic white people, and fewer patients from other racial and ethnic backgrounds. “Ensuring that pwCF [people with…

Reducing the dose of Kaftrio (elexacaftor, tezacaftor, and ivacaftor) should be considered for cystic fibrosis (CF) patients who report cognitive and psychological side effects, a study in Ireland suggests. Such patients should have an individualized dosage to minimize side effects while maintaining CFTR modulator therapy. “Dose reduction…

High blood sugar can impair the ability to utilize oxygen for energy with cystic fibrosis (CF), which may explain why exercise can be especially tiring for those with the disease, a new study shows. Researchers think the biological mechanism responsible for this phenomenon is that high blood sugar can…

The Cystic Fibrosis Foundation is funding up to $3.9 million to TB Alliance to conduct preclinical studies of a compound that could be used to treat infections caused by nontuberculous mycobacteria (NTM) in people with cystic fibrosis (CF). These infections often require antibiotic treatment for more…

Roughly 200 paddlers are set to cross the Atlantic Ocean’s Gulf Stream on June 25 to support cystic fibrosis (CF) families through the Piper’s Angels Foundation, marking the fundraiser’s 10th anniversary. The long-distance endurance paddle challenge and international championship race has raised more than $2.7 million to date…

A class of therapies called PDE4 inhibitors, which are approved to manage certain inflammatory diseases, may help boost the functionality of the protein whose defect causes cystic fibrosis (CF), according to a new study. Results also suggest that some available CF treatments may be effective in a broader array…

Taking Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., for up to 24 weeks can make signs of inflammation go down in people with cystic fibrosis (CF), and help get rid of Pseudomonas aeruginosa bacteria. That’s according to data from a…

First Wave BioPharma has completed patient screening for the Phase 2 SPAN clinical trial of a new formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. The trial (NCT05719311) will be conducted at three sites in Florida, Illinois, and Nevada, and include…

A young man with cystic fibrosis (CF) has become the first patient in the U.S. to undergo MRI lung imaging combined with Xenoview, a novel technology by Polarean Imaging for visualizing lung ventilation. The scan, done in a 19-year-old CF patient, took place at the Cincinnati Children’s Hospital…